{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T17:53:24Z","timestamp":1774288404621,"version":"3.50.1"},"reference-count":31,"publisher":"S. Karger AG","issue":"2","license":[{"start":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:00:00Z","timestamp":1744588800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:00:00Z","timestamp":1744588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Haematol"],"abstract":"<jats:p>Introduction: We conducted a single-arm, open-label dose-exploration study to evaluate the safety and efficacy of the histone deacetylase inhibitor tucidinostat combined with bortezomib, liposomal doxorubicin, and dexamethasone (C-PDD) in treating relapsed and refractory multiple myeloma (RRMM) patients. Methods: Eighteen patients were enrolled from August 2020 to May 2021, receiving 21-day cycles of C-PDD. Results: Eighteen cases were analysed, with a median prior treatment line of 2 (range: 1\u20134). The median number of completed treatment cycles was 4 (range: 1\u20138). The overall response rate was 57%, including 14% complete response, 14% very good partial response, and 29% partial response. Both bortezomib-sensitive and refractory groups had a response rate of 57%. The response rate was 100% in patients with extramedullary extraosseous involvement. The median follow-up was 42 months (range: 3\u201344), with median progression-free survival of 7 months and median overall survival of 24.5 months. Grade 3\u20134 haematologic adverse events included thrombocytopaenia (50%), neutropenia (33%), and anaemia (33%). Non-haematologic adverse events were mostly grade 1\u20132, with 1 case of grade 3 peripheral sensory neuropathy. Conclusion: The C-PDD regimen showed efficacy in RRMM, including bortezomib-refractory disease and EME patients. The optimal dose and combination need to be explored in the future.<\/jats:p>","DOI":"10.1159\/000545709","type":"journal-article","created":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T12:00:38Z","timestamp":1744632038000},"page":"211-220","source":"Crossref","is-referenced-by-count":1,"title":["Tucidinostat Combined with Bortezomib, Liposomal Doxorubicin, and Dexamethasone in Multiple Myeloma Treatment"],"prefix":"10.1159","volume":"149","author":[{"given":"Jingyi","family":"Bi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuelin","family":"Dou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruqi","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8471-8460","authenticated-orcid":false,"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoguang","family":"Lei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liru","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huixia","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingdi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2025,4,14]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01513"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0706-9"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2014.55"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.196"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.703233"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0119-y"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.4161\/15592294.2014.983367"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2008.03.037"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2536759100"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.10.5460"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-06-1768"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.01.133"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.05.007"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14889"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1039\/c4md00350k"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA7003"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2017.01.025"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.181172"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-2414-3"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-012-1847-5"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv237"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(16)30206-6"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-11-0433"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13799"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.29"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-010-1052-8"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12325"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.51"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.189969"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-01-481325"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(14)70440-1"}],"container-title":["Acta Haematologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/aha\/article-pdf\/doi\/10.1159\/000545709\/4365275\/000545709.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000545709","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T17:01:26Z","timestamp":1774285286000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000545709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,14]]},"references-count":31,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,3,23]]},"published-print":{"date-parts":[[2026,3,26]]}},"URL":"https:\/\/doi.org\/10.1159\/000545709","archive":["Portico"],"relation":{},"ISSN":["0001-5792","1421-9662"],"issn-type":[{"value":"0001-5792","type":"print"},{"value":"1421-9662","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,14]]}}}